NateraNTRA
Market Cap: $13.9B
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 3,293
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
197% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 32
62% more call options, than puts
Call options by funds: $49.7M | Put options by funds: $30.7M
26% more repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 145
25% more funds holding in top 10
Funds holding in top 10: 20 [Q1] → 25 (+5) [Q2]
20% more capital invested
Capital invested by funds: $10.9B [Q1] → $13B (+$2.18B) [Q2]
16% more funds holding
Funds holding: 406 [Q1] → 469 (+63) [Q2]
0.4% less ownership
Funds ownership: 98.51% [Q1] → 98.1% (-0.4%) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Canaccord Genuity Kyle Mikson 38% 1-year accuracy 8 / 21 met price target | 28%upside $145 | Buy Maintained | 27 Aug 2024 |
Morgan Stanley Tejas Savant 69% 1-year accuracy 11 / 16 met price target | 17%upside $132 | Overweight Maintained | 13 Aug 2024 |
Piper Sandler David Westenberg 55% 1-year accuracy 16 / 29 met price target | 33%upside $150 | Overweight Maintained | 13 Aug 2024 |
TD Cowen Dan Brennan 61% 1-year accuracy 17 / 28 met price target | 28%upside $145 | Buy Maintained | 9 Aug 2024 |
BTIG Mark Massaro 63% 1-year accuracy 17 / 27 met price target | 20%upside $135 | Buy Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 5 articles about NTRA published over the past 30 days